Literature DB >> 9376213

Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors.

P H Sugden1, A Clerk.   

Abstract

The extracellularly-responsive kinase (ERK) subfamily of mitogen-activated protein kinases (MAPKs) has been implicated in the regulation of cell growth and differentiation. Activation of ERKs involves a two-step protein kinase cascade lying upstream from ERK, in which the Raf family are the MAPK kinase kinases and the MEK1/MEK2 isoforms are the MAPK kinases. The linear sequence of Raf --> MEK --> ERK constitutes the ERK cascade. Although the ERK cascade is activated through growth factor-regulated receptor protein tyrosine kinases, they are also modulated through G protein-coupled receptors (GPCRs). All four G protein subfamilies (Gq/11 Gi/o, Gs and G12/13) influence the activation state of ERKs. In this review, we describe the ERK cascade and characteristics of its activation through GPCRs. We also discuss the identity of the intervening steps that may couple agonist binding at GPCRs to activation of the ERK cascade.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376213     DOI: 10.1016/s0898-6568(96)00191-x

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  57 in total

1.  ERKI/II regulation by the muscarinic acetylcholine receptors in neurons.

Authors:  K Rosenblum; M Futter; M Jones; E C Hulme; T V Bliss
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

2.  Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells.

Authors:  Jie Xu; Bo Jian; Richard Chu; Zhibin Lu; Quanyi Li; John Dunlop; Sharon Rosenzweig-Lipson; Paul McGonigle; Robert J Levy; Bruce Liang
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Eicosanoids inhibit the G-protein-gated inwardly rectifying potassium channel (Kir3) at the Na+/PIP2 gating site.

Authors:  S L Rogalski; C Chavkin
Journal:  J Biol Chem       Date:  2001-02-07       Impact factor: 5.157

Review 4.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 5.  ABCC6 as a target in pseudoxanthoma elasticum.

Authors:  András Váradi; Zalán Szabó; Viola Pomozi; Hugues de Boussac; Krisztina Fülöp; Tamás Arányi
Journal:  Curr Drug Targets       Date:  2011-05       Impact factor: 3.465

6.  Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822.

Authors:  David Wirtshafter
Journal:  Pharmacol Biochem Behav       Date:  2007-01-20       Impact factor: 3.533

7.  Identification of MEK1 as a novel target for the treatment of neuropathic pain.

Authors:  A Ciruela; A K Dixon; S Bramwell; M I Gonzalez; R D Pinnock; K Lee
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  Epidermal-growth-factor receptor and metalloproteinases mediate thromboxane A2-dependent extracellular-signal-regulated kinase activation.

Authors:  Carole Gallet; Stéphanie Blaie; Sylviane Lévy-Toledano; Aïda Habib
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

9.  Specific and differential activation of mitogen-activated protein kinase cascades by unfamiliar taste in the insular cortex of the behaving rat.

Authors:  D E Berman; S Hazvi; K Rosenblum; R Seger; Y Dudai
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

10.  NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth.

Authors:  Irina M Jaba; Zhen W Zhuang; Na Li; Yifeng Jiang; Kathleen A Martin; Albert J Sinusas; Xenophon Papademetris; Michael Simons; William C Sessa; Lawrence H Young; Daniela Tirziu
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.